Combining Daratumumab with VRd Improves Outcomes in Patients with Transplant-Ineligible or Transplant-Deferred Newly Diagnosed Multiple Myeloma By Ogkologos - March 3, 2025 548 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CEPHEUS study Source RELATED ARTICLESMORE FROM AUTHOR The Legacy of the ESMO Patient Engagement Summit 2025: Advancing Rights of Patients with Cancer via Cross-Border Best Practices and Collaboration Sustained PFS Benefit of Imlunestrant Over SoC in Patients with ESR1-mutated Advanced Breast Cancer ESMO Welcomes Launch of Health Package Introducing EU Measures That Can Boost Innovation in Oncology and Help Prevent New Cancer Cases MOST POPULAR Prising open the trap: Getting to grips with targeted cancer drug... January 10, 2022 A Combination of Trifluridine-Tipiracil Plus Bevacizumab Results in Longer Overall Survival... May 9, 2023 Men’s skin cancer rates increase by 50% over decade June 24, 2021 Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση December 18, 2019 Load more HOT NEWS Sacituzumab Govitecan Improves Outcomes Over Single-Agent Chemotherapy in Patients with Pretreated... Woman Has Unnecessary Double Mastectomy and Narrowly Avoids Hysterectomy After Bad... Mom Walks In To Comfort Scared Son After Surgery And Sees... Patient Guide in Prostate Cancer Now Available Also in German
